
Gilead Sciences
GILD · NASDAQ · Biotechnology
Quotes delayed up to 15 min. Updated 16 Nov, 16:00 New York time
- Market cap
- $208 bn
- Div. yield
- 4,0%
- Year to date
- +36,9%
Ratio score
based on 8 metrics as of 16.11.2026 ·
Verdict by our methodology based on current metrics. Not an investment recommendation.
Key metrics
1 ✓ · 2 — · 5 ✕ · 2 n/a · hover over a row or tap it to see the trend
All metrics
| Metric | Value | 5-year median | Industry median |
|---|---|---|---|
| P/E TTM | n/a | 18,6 | 42,1 |
| Forward P/E | 20,9 | — | 18,7 |
| PEG | n/a | — | 4,1 |
| P/S | 6,7 | 3,8 | 6,6 |
| EV/EBITDA | 18,8 | 15,3 | 28,2 |
| P/FCF | 15,1 | — | 26,0 |
| P/B | 16,1 | 5,1 | 9,8 |
Industry median — across 6 profitable companies in “Biotechnology” in Ratio. Revenue and EPS forecasts for future years and the number of employees are in the paid data plan.
Price chart
Compare with
Choose a stock
Closing prices adjusted for splits and dividends. The S&P 500 index and the intraday chart come later.
Analysts
Ratings, 36 analysts
- Buy
- 30
- Hold
- 6
- Sell
- 0
Beat the EPS forecast in 4 of the last 4 quarters
| Quarter | Estimate | Actual | Surprise |
|---|---|---|---|
| Q3 2026 | 2,23 | 2,55 | Up +14,3% |
| Q2 2026 | −7,38 | −6,75 | Up +8,5% |
| Q1 2026 | 1,95 | 2,03 | Up +4,0% |
| Q4 2025 | 1,85 | 1,86 | Up +0,7% |
Price targets and yearly revenue and EPS forecasts are in the paid data plan. These are analysts' opinions, not our verdict.
Financials in charts
| Metric | Q3'26 | Q2'26 | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 | Q1'24 | Q4'23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 8,30 bn | 7,80 bn | 6,96 bn | 7,93 bn | 7,77 bn | 7,08 bn | 6,67 bn | 7,57 bn | 7,55 bn | 6,95 bn | 6,69 bn | 7,11 bn |
| EPS | 1,94 | −8,45 | 1,61 | 1,74 | 2,43 | 1,56 | 1,04 | 1,42 | 1,00 | 1,29 | −3,34 | 1,13 |
| Margin | 29,3% | −134,5% | 29,0% | 27,5% | 39,3% | 27,7% | 19,7% | 23,6% | 16,6% | 23,2% | −62,4% | 20,1% |
| FCF | 4,80 bn | 3,43 bn | 2,43 bn | 3,12 bn | 3,96 bn | 720 m | 1,65 bn | 2,83 bn | 4,17 bn | 1,20 bn | 2,11 bn | 1,95 bn |
From SEC reports. TTM is the sum of 4 quarters; a year is TTM at the end of the calendar year. Forecast bars are in the paid data plan.
Owners
Ownership structure and major holders (13F filings) are in the paid data plan. They are not part of the score or the traffic light.
Insider trades over 12 months
Over 12 months: no purchases, sales $106 m.
| Name | Amount | Shares | Price |
|---|---|---|---|
| cain wettan keeley m6 Nov 2026 · sale | $557 810 | 3 399 | $164,11 |
| o'day daniel patrick5 Nov 2026 · sale | $1,72 m | 9 810 | $175,17 |
| o'day daniel patrick4 Nov 2026 · sale | $18,0 m | 102 619 | $175,16 |
| o'day daniel patrick2 Nov 2026 · sale | $342 125 | 2 000 | $171,06 |
| o'day daniel patrick2 Nov 2026 · sale | $1,33 m | 7 796 | $170,35 |
| o'day daniel patrick2 Nov 2026 · sale | $322 296 | 1 904 | $169,27 |
| o'day daniel patrick2 Nov 2026 · sale | $285 771 | 1 700 | $168,10 |
| o'day daniel patrick2 Nov 2026 · sale | $267 840 | 1 600 | $167,40 |
| o'day daniel patrick30 Oct 2026 · sale | $2,78 m | 15 881 | $175,25 |
| mercier johanna15 Oct 2026 · sale | $468 660 | 3 000 | $156,22 |
| dickinson andrew d15 Oct 2026 · sale | $468 660 | 3 000 | $156,22 |
| o'day daniel patrick1 Oct 2026 · sale | $445 880 | 3 000 | $148,63 |
| o'day daniel patrick1 Oct 2026 · sale | $1,77 m | 12 000 | $147,72 |
| mercier johanna15 Sep 2026 · sale | $87 174 | 600 | $145,29 |
| mercier johanna15 Sep 2026 · sale | $115 566 | 800 | $144,46 |
SEC Form 4. Titles and trading plans are not in the data. They are not part of the score or the traffic light.
About the company
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Country
- US
- IPO date
- 22 Jan 1992
- Website
- www.gilead.com
Company description, revenue by segment and region, and the CEO will come later.
Earnings
- Next report
- date not announced
An AI summary of the earnings call will come later.
Peers
| Company | Price | ||||
|---|---|---|---|---|---|
AMGNAmgen | $462,32 | 67★★★★★★★★★would watch | 26,8 | +8,2% | 24,1% |
VRTXVertex Pharmaceuticals | $537,79 | 72★★★★★★★★★would consider | 33,7 | +10,5% | 30,7% |
REGNRegeneron Pharmaceuticals | $952,40 | 67★★★★★★★★★would watch | 20,5 | +18,6% | 28,5% |
MRNAModerna | $215,27 | 22★★★★★★would not consider | — | +13,1% | −110,5% |
ABBVAbbVie | $294,55 | 72★★★★★★★★★would consider | 50,4 | +10,7% | 15,7% |
Ratio — a score by our methodology, not an investment recommendation.




